Latest Pharmaceutical Development News

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Prescient Therapeutics has reached a pivotal milestone by dosing the first patient in its Phase 2a clinical trial of PTX-100 for relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), aiming to evaluate safety and efficacy across multiple international sites.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.